Dismissed members of CDC vaccine committee call Kennedy's actions 'destabilizing'
NEW YORK (AP) — All 17 experts recently dismissed from a government vaccine advisory panel published an essay Monday decrying 'destabilizing decisions' made by U.S. Health Secretary Robert F. Kennedy Jr. that could lead to more preventable disease spread.
Kennedy last week announced he would 'retire' the entire panel that guides U.S. vaccine policy. He also quietly removed Dr. Melinda Wharton — the veteran Centers for Disease Control and Prevention official who coordinated the committee's meetings.
Two days later, he named eight new people to the influential panel. The list included a scientist who criticized COVID-19 vaccines, a leading critic of pandemic-era lockdowns and someone who worked with a group widely considered to be a leading source of vaccine misinformation.
'We are deeply concerned that these destabilizing decisions, made without clear rationale, may roll back the achievements of U.S. immunization policy, impact people's access to lifesaving vaccines, and ultimately put U.S. families at risk of dangerous and preventable illnesses,' the 17 panelists wrote in the Journal of the American Medical Association.
The new committee is scheduled to meet next week. The agenda for that meeting has not yet been posted, but a recent federal notice said votes are expected on vaccinations against flu, COVID-19, HPV, RSV and meningococcal bacteria.
The removal of Wharton and CDC immunization staff cuts will make it hard for a group of new outside advisers to quickly come up to speed and make fact-based decisions about what vaccines to recommend and not recommend to the public, the experts said.
'The termination of all members and its leadership in a single action undermines the committee's capacity to operate effectively and efficiently, aside from raising questions about competence,' they wrote.
A spokeswoman for the U.S. Department of Health and Human Services did not respond to the JAMA commentary, but instead pointed to Kennedy's previous comments on the committee.
Kennedy, a leading voice in the anti-vaccine movement before becoming the U.S. government's top health official, has accused the committee of being too closely aligned with vaccine manufacturers and of rubber-stamping vaccines.
The Advisory Committee on Immunization Practices, created in 1964, makes recommendations to the CDC director on how vaccines that have been approved by the Food and Drug Administration should be used. CDC directors almost always approve those recommendations, which are widely heeded by doctors and guide vaccination programs.
ACIP policies require members to state past collaborations with vaccine companies and to recuse themselves from votes in which they had a conflict of interest, but Kennedy has dismissed those safeguards as weak.
___
The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute's Science and Educational Media Group and the Robert Wood Johnson Foundation. The AP is solely responsible for all content.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
28 minutes ago
- Yahoo
3 Top Genomics Stocks to Add to Your Portfolio in 2025
An updated edition of the March 28, 2025, article. The rapid evolution of genomics, the study of genes and their functions, in recent times has paved the way for a revolutionary era in genetic medicine. Given the constant need for innovative medical treatments, genomics holds the key to the future of the medical world. In simpler terms, genomics includes the study of a complete set of genes, their work process and way of interacting with each other and the environment. The primary focus is to evaluate all the genes of an organism rather than individual genes. Of late, there have been several breakthroughs in this field, attracting the attention of pharma and biotech companies. Genetic information is being used to evaluate individual responses to drugs, leading to the development of targeted therapies. Interestingly, genomics has ushered in innovative concepts, such as synthetic biology, which applies engineering principles to biology. Synthetic biology products serve life sciences researchers across a variety of healthcare applications, including drug discovery, disease detection, enzyme engineering, gene editing and basic academic research. The recent spotlight on companies in the evolving genomics sector can be attributed to a drastic reduction in the cost, accuracy, and time required to map an individual's entire genome. A major player in this field is Illumina ILMN, a global leader in sequencing and array-based solutions for genetic and genomic analysis. While some companies are utilizing genetic sequencing to develop solutions not only for healthcare but also for other areas, diagnostic companies leverage sequencing data to identify specific genetic variations and map them to a known condition. Another breakthrough is the development of genome editing approaches, such as CRISPR/Cas9 technology. Gene editing companies, such as BEAM Therapeutics BEAM and CRISPR Therapeutics AG CRSP, hold potential to treat and cure diseases caused by genetic variants. As the name suggests, they make changes or correct defects in the organism's DNA. Per estimates, the genomics market will reach $157.47 billion by 2033. Per Grandview research, the global synthetic biology market size was valued at $16.22 billion in 2024 and is projected to witness a CAGR of 17.30% from 2025 to 2030. If you're looking to capitalize on this trend, our Genomics and Synthetic Biology screen makes it easy to identify high-potential stocks at any given time. At present, investors can consider adding stocks like Intellia Therapeutics NTLA, uniQure QURE and Verve Therapeutics VERV to their portfolio. Explore 30 cutting-edge investment themes with Zacks Thematic Screens and uncover your next big opportunity. Intellia Therapeutics is a clinical-stage gene editing company, focused on developing drugs with CRISPR-based therapies. NTLA is leveraging its modular platform to advance in vivo and ex vivo therapies for diseases with high unmet need. The in vivo programs use CRISPR to enable precise editing of disease-causing genes directly inside the human body. NTLA's lead in vivo product candidates are nex-z for the treatment of ATTR amyloidosis and NTLA-2002 for the treatment of HAE. NTLA-2002 is a wholly owned, investigational in vivo CRISPR-based therapy designed to knock out the kallikrein B1 gene in the liver, with the goal of achieving lifelong control of HAE attacks after a single dose. Nex-z is an investigational CRISPR-based therapy designed to inactivate the TTR gene in liver cells, thereby preventing the production of TTR protein for the treatment of ATTR amyloidosis. Both are currently in phase III studies. NTLA has collaborated with Regeneron for Nex-z. This Zacks Rank #2 (Buy) company is also advancing ex vivo applications to address immuno-oncology and autoimmune diseases, where CRISPR is used as the tool to create the engineered cell therapy outside the body. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. uniQure is advancing a focused pipeline of innovative gene therapies for the treatment of Huntington's disease, amyotrophic lateral sclerosis caused by mutations in superoxide dismutase 1 ('SOD1-ALS'), refractory mesial temporal lobe epilepsy ('mTLE') and Fabry disease. The company has made good pipeline progress. The FDA recently granted Breakthrough Therapy designation to AMT-130 for the treatment of Huntington's disease. In March 2025, QURE held a Type B meeting with the FDA to discuss chemistry, manufacturing and controls requirements for AMT-130, in support of a planned biologics license application ('BLA') submission. An additional Type B meeting (focused on the pivotal statistical analysis plan) was also held. The company is also conducting a phase I/IIa study (GenTLE) on AMT-260 for the treatment of MTLE in the United States. A phase I/IIa study on AMT-191 for the treatment of Fabry disease is also ongoing. AMT-162 is being evaluated for the treatment of SOD1-ALS in a phase I/II study. The successful development of any of these candidates will be a significant boost for this Zacks Rank #2 company. Verve Therapeutics is a clinical-stage company developing a new class of genetic medicines for cardiovascular disease (CVD). The primary objective is to transition CVD treatment from chronic therapies to single-course, gene-editing medicines. VERV is developing a pipeline of gene editing programs targeting the three lipoprotein pathways — low-density lipoprotein, or LDL, triglyceride-rich lipoproteins, and lipoprotein(a), or Lp(a) — that drive atherosclerotic cardiovascular disease (ASCVD), the most common form of CVD. VERV's lead clinical-stage programs target the PCSK9 and ANGPTL3 genes, which have been extensively validated as targets for lowering LDL cholesterol, or LDL-C. VERVE-102 targets PCSK9 and is designed to permanently turn off the PCSK9 gene in the liver. The candidate is being evaluated in the open-label phase Ib Heart-2 study. The study is designed to evaluate the safety and tolerability of VERVE-102 in adult patients with heterozygous familial hypercholesterolemia, or HeFH, and/or premature coronary artery disease. VERVE-201 is designed to permanently turn off the ANGPTL3 gene in the liver. VERVE-201 is being evaluated in the open-label phase Ib study designed to evaluate the safety and tolerability in adult patients with refractory hypercholesterolemia. VERVE-301 is being developed in collaboration with Lilly. The company also carries a Zacks Rank #2. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Illumina, Inc. (ILMN) : Free Stock Analysis Report Beam Therapeutics Inc. (BEAM) : Free Stock Analysis Report uniQure N.V. (QURE) : Free Stock Analysis Report Intellia Therapeutics, Inc. (NTLA) : Free Stock Analysis Report CRISPR Therapeutics AG (CRSP) : Free Stock Analysis Report Verve Therapeutics, Inc. (VERV) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
30 minutes ago
- Yahoo
Scientists Discover Startling Trick to Defeat Insomnia
Insomnia is a curse we wouldn't wish on our worst enemy — and scientists have discovered a startlingly simple lifestyle change that appears to be very statistically effective at preventing it. In a new study published in the journal Sleep Health, researchers from Columbia and the University of Chicago report that eating a full day's serving worth of fruits and vegetables strongly appears to help people sleep more soundly throughout the night. Interrupted sleep, which is known as "sleep fragmentation" to researchers, has been found to induce a litany of grim health outcomes ranging from heart failure to diabetes and cognitive problems to cognitive dysfunction. One major culprit might be a familiar one to many participants in our industrial food system: poor nutrition lacking in fresh fruits and veggies. The researchers recruited 34 healthy young adults with an average age of 28 years old who had no known sleep issues before. The participants were tasked with tagging their food input into an app for 201 days, and wore wrist monitors that tracked their sleep throughout. After analyzing the data from the app and wrist monitors with statistical modeling, the researchers found that sleep quality can improve up to a staggering 16 percent after eating five cups of fruit and vegetables — the Centers for Disease Control and Prevention's definition of a full day's serving — as compared to a diet that lacks produce. What's more, the effects were effectively instantaneous: sleep improvements took place the very same nights that participants reported eating lots of fruits and vegetables. "It's remarkable that such a meaningful change could be observed within less than 24 hours," explained UChicago sleep expert Esra Tasali said in the school's press release. Though 16 percent may not seem like much, Tasali characterized it as a "highly significant difference." It's possible, per Columbia's statement on the study, that the amino acid tryptophan — the same one cited in anecdata about getting sleepy post-Thanksgiving turkey — might be responsible. Fruits and vegetables contain carbohydrates that help the brain absorb tryptophan, Columbia explains, which in turn helps aid the production of the sleepy hormone melatonin. Though you can purchase synthetic melatonin supplements at the store, it's tastier and healthier to get your brain to produce it for you by eating produce. Five cups may seem a bit daunting, but the researchers insist that eating more fruits and vegetables in general can help you sleep better even if you don't reach that full serving. "People are always asking me if there are things they can eat that will help them sleep better," author Marie-Pierre St-Onge, the director of Columbia's sleep center, said in the school's press release. "Small changes can impact sleep. That is empowering — better rest is within your control." More on sleep: You Can See When Elon Musk Actually Sleeps by Analyzing His Tweets, and It's Terrifying


Fast Company
35 minutes ago
- Fast Company
The real reason wellness programs fail? No one uses them
Fast Company recently posed the question: 'Why isn't your workplace wellness program reducing stress?' The answer, as the article rightly pointed out, isn't about bad intentions—it's about bad execution. Most wellness initiatives are still treating symptoms, not causes. But we need to go even deeper. Workplace wellness isn't failing because it's frivolous. It's failing because employees aren't engaging with it. Stressed and burned out Corporate America spends an estimated $65 billion a year on wellness perks, from mindfulness apps to meditation pods yet 77% of employees still report feeling stressed, and 82% say they're at risk of burnout. In the largest academic study of U.S. programs, fewer than half of eligible employees ever engaged with the resources on offer (RAND Corporation). Digital-only benefits fare even worse: 'app sprawl' and discovery fatigue mean that most perks are forgotten before they're used. A meditation app buried in a browser tab can't move the needle on mental health, absenteeism, or retention. It's easy to blame employees for being disengaged, or to point fingers at toxic culture. But the truth is more subtle—and more solvable. Complexity kills engagement When HR teams assemble a buffet of stand-alone apps—financial coaching here, sleep tools there, therapy platforms somewhere else—every login is another cognitive task. Overwhelmed workers don't skip your yoga discount because they dislike yoga. They skip it because they don't remember where the link lives. At YuLife, we partnered with the University of Essex to study this problem. We found that bundling insurance, rewards, virtual care, and micro-challenges into one gamified experience radically changed engagement patterns: Users take healthy actions on 20 of 30 days, double the norm 54% return monthly, 50% engage daily Daily steps rose 13%, equivalent to adding 4.5 years of life expectancy Self-reported stress dropped 53%, productivity rose 57% Crucially, activity inside the app predicted use of other benefits. Those included 4× more Employee Assistance Program utilization, 2.4× more virtual GP visits, an 11.5% drop in absenteeism, and a 2.75% drop in turnover Engagement is the missing variable Wellness programs aren't underperforming because employees don't care. They're underperforming because the programs weren't designed with real behavioral engagement in mind. Three blockers we can eliminate today: Perk fragmentation Consolidate your well-being tools. If it takes more than two clicks or logins, it's too much. Build a single front door, ideally integrated where work already happens (Slack, Teams, a unified app). Slow-burn rewards Points that take months to redeem lose meaning. When users can swap earned 'coins' for gift cards the same week, engagement jumps 30% and rises again with leaderboards or friendly duels. One-size-fits-all content A new parent, a cyclist, and a burnt-out manager don't need the same nudges. Personalised AI-driven prompts that respond to user behaviour drive a 3x increase in healthy habits. Well-being is infrastructure, not a perk We often hear that wellness is 'hard to measure.' But that's usually a reflection of low engagement, not flawed strategy. At 20% adoption, noise drowns out signals. At 50%+, the ROI becomes clear, including a 5% drop in claims costs for employers integrating preventive data into group-risk underwriting. If fewer than half your people open the app, the program doesn't work. No matter how many perks you fund.